MyX Therapeutics Inc.
http://myxthera.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MyX Therapeutics Inc.
Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice